obodence

Obodence is a biosimilar of denosumab, developed by Samsung Bioepis, and is approved in the European Union for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures, bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and bone loss associated with long-term systemic glucocorticoid therapy in adults at increased risk of fracture. Denosumab is a fully human monoclonal IgG2 antibody produced using recombinant DNA technology in Chinese hamster ovary cells. It acts as a RANK ligand inhibitor by binding to RANKL (receptor activator of nuclear factor kappa-B ligand), thereby preventing its interaction with the RANK receptor on osteoclasts and their precursors. This inhibition reduces osteoclast formation, function, and survival—ultimately decreasing bone resorption and increasing bone mass[1][2][4][5].

Brand names

Obodence

Other names

denosumab-dssb